Next report date
—
Report period
—
EPS estimate
—
Revenue estimate
—
−2.13 USD
−35.12 M USD
0.00 USD
51.48 M
About Climb Bio, Inc.
Sector
Industry
CEO
Aoife M. Brennan
Website
Headquarters
Wellesley Hills
Founded
2018
FIGI
BBG00ZNKL0K6
Climb Bio, Inc. operates as a clinical-stage biotechnology company. It develops therapeutics for patients with immune-mediated diseases. Its lead product candidate, budoprutug, is an anti-CD19 antibody designed for a broad range of B-cell mediated diseases. The company was founded by Andrew D. Levin and Valerie Morisset on October 18, 2018 and is headquartered in Wellesley Hills, MA.
Displays a symbol's price movements over previous years to identify recurring trends.
Frequently Asked Questions
The current price of CLYM is 3.05 USD — it has increased by 1.67% in the past 24 hours. Watch Climb Bio, Inc. stock price performance more closely on the chart.
Depending on the exchange, the stock ticker may vary. For instance, on NASDAQ exchange Climb Bio, Inc. stocks are traded under the ticker CLYM.
CLYM stock has fallen by −5.57% compared to the previous week, the month change is a −34.55% fall, over the last year Climb Bio, Inc. has showed a 16.86% increase.
CLYM reached its all-time high on Aug 30, 2021 with the price of 29.69 USD, and its all-time low was 2.21 USD and was reached on Feb 17, 2023. View more price dynamics on CLYM chart.
See other stocks reaching their highest and lowest prices.
See other stocks reaching their highest and lowest prices.
CLYM stock is 9.95% volatile and has beta coefficient of 0.10. Track Climb Bio, Inc. stock price on the chart and check out the list of the most volatile stocks — is Climb Bio, Inc. there?
Today Climb Bio, Inc. has the market capitalization of 205.03 M, it has decreased by −0.33% over the last week.
Yes, you can track Climb Bio, Inc. financials in yearly and quarterly reports right on TradingView.
Climb Bio, Inc. is going to release the next earnings report on Mar 4, 2025. Keep track of upcoming events with our Earnings Calendar.
CLYM net income for the last quarter is −8.89 M USD, while the quarter before that showed −54.89 M USD of net income which accounts for 83.79% change. Track more Climb Bio, Inc. financial stats to get the full picture.
No, CLYM doesn't pay any dividends to its shareholders. But don't worry, we've prepared a list of high-dividend stocks for you.
As of Nov 25, 2024, the company has 9.00 employees. See our rating of the largest employees — is Climb Bio, Inc. on this list?
Like other stocks, CLYM shares are traded on stock exchanges, e.g. Nasdaq, Nyse, Euronext, and the easiest way to buy them is through an online stock broker. To do this, you need to open an account and follow a broker's procedures, then start trading. You can trade Climb Bio, Inc. stock right from TradingView charts — choose your broker and connect to your account.
Investing in stocks requires a comprehensive research: you should carefully study all the available data, e.g. company's financials, related news, and its technical analysis. So Climb Bio, Inc. technincal analysis shows the sell today, and its 1 week rating is sell. Since market conditions are prone to changes, it's worth looking a bit further into the future — according to the 1 month rating Climb Bio, Inc. stock shows the sell signal. See more of Climb Bio, Inc. technicals for a more comprehensive analysis.
If you're still not sure, try looking for inspiration in our curated watchlists.
If you're still not sure, try looking for inspiration in our curated watchlists.